Medicare Launches Pilot Expanding Access to GLP-1 Drugs
Medicare is opening a narrow but significant door for weight-loss drug coverage.
Starting next month, eligible beneficiaries will be able to access certain GLP-1 medications through a new pilot program — something federal law has generally not allowed Medicare to do when the drugs are prescribed specifically for weight loss.
What the Program Actually Covers
The Medicare GLP-1 Bridge Program begins July 1 and will provide select GLP-1 drugs to qualifying Medicare Part D enrollees.
Three medications are included: Wegovy, in both injectable and tablet form; the KwikPen formulation of Zepbound; and Foundayo, a newer GLP-1 pill from Eli Lilly.
Eligible patients will pay a fixed monthly copayment of $50 for these medications, regardless of dosage or which stage of their Part D benefit they're in.
That fixed price matters because cash prices for these drugs otherwise range widely — NPR reported Zepbound's KwikPen can run up to $699 a month without the program, while Wegovy and Foundayo's highest doses cost $299 and $349 respectively.
📰 Related: Your Omega-3 Supplement May Not Help Your Brain
Who Actually Qualifies
Eligibility is built around BMI thresholds combined with specific health conditions, not simply a desire to lose weight.
To qualify, a person must be 18 or older and meet one of three criteria: a BMI of 35 or higher; a BMI of 30 or higher paired with conditions such as heart failure, uncontrolled hypertension, or chronic kidney disease; or a BMI of 27 or higher combined with risk factors including prediabetes, heart attack, or peripheral artery disease.
According to the Medicare Rights Center, people already taking a GLP-1 for weight loss before the program starts may still qualify, provided their prescriber attests they met the relevant BMI threshold when they originally began the medication — even if weight loss has since brought their current BMI below that threshold.
A centralized system, separate from each beneficiary's individual Part D plan, will handle prior authorization, claims processing, and pharmacy payments for the entire program.
📰 Related: Australia Confirms First H5N1 Case, Completing Global Spread
Why Federal Law Made This Necessary in the First Place
Under existing federal law, Medicare Part D plans cannot cover medications prescribed specifically for weight loss, among several other excluded drug categories.
That restriction holds even for drugs that are FDA-approved for multiple uses. A GLP-1 prescribed for type 2 diabetes or cardiovascular risk reduction can already be covered under standard Part D; the same drug prescribed purely for weight loss cannot, unless Congress changes the underlying law.
The Bridge Program works around that limitation by operating entirely outside the normal Part D benefit structure, rather than attempting to amend what Part D itself is allowed to cover.
That structural choice has a real tradeoff: the $50 copay won't count toward a beneficiary's Part D deductible or their annual out-of-pocket spending cap, and the Medicare Extra Help low-income subsidy cannot be applied to it.
📰 Related: Your Coffee Brewing Method Affects Cholesterol and Dementia Risk
The Quiet Extension Nobody Announced Loudly
The Bridge Program wasn't originally supposed to last this long.
When CMS first proposed the framework, the plan was for the Bridge to run only through the end of 2026, serving as a short stopgap before a more permanent program called the BALANCE Model took over in January 2027.
That handoff didn't happen as planned. In May, CMS announced it was delaying the Part D portion of the BALANCE Model indefinitely — and extended the Bridge Program's runway through December 31, 2027, to cover the gap that delay created.
In effect, what was designed as a six-month bridge to a permanent solution has become a nearly eighteen-month standalone program, with the actual long-term replacement now pushed to a 2028 start that itself remains unconfirmed.
What Happens When the Bridge Ends
The program's temporary nature carries a specific clinical risk that outlasts the coverage window itself.
Research has consistently shown that many people who stop taking GLP-1 medications regain a substantial portion of the weight they lost while on them.
That creates a genuine planning question for anyone who starts the medication under the Bridge Program: coverage is guaranteed only through the end of 2027, and what replaces it — if anything — has already been delayed once already.
For now, beneficiaries don't need to register or take any action ahead of the July 1 launch; CMS has said more detailed guidance on accessing the program will be released before then.
Key Takeaways
- The Medicare GLP-1 Bridge Program begins July 1, 2026, providing coverage for Wegovy, Zepbound (KwikPen), and Foundayo to eligible Medicare Part D enrollees.
- Eligible beneficiaries will pay a fixed $50 monthly copayment, regardless of dosage.
- Eligibility requires a BMI of 35+, or 30+ with conditions like heart failure or chronic kidney disease, or 27+ with risk factors including prediabetes or prior heart attack.
- The program runs outside standard Part D coverage, meaning the copay doesn't count toward deductibles, out-of-pocket caps, or Extra Help subsidies.
- The program was extended through December 2027 after CMS indefinitely delayed the permanent BALANCE Model originally planned to begin in 2027.
- Many patients regain weight after stopping GLP-1 medications, raising questions about what happens when the Bridge Program eventually ends.
Sources
Also Read
Health & Science Correspondent
Dr. Chris Farley brings a medical background to his reporting on healthcare policy, scientific research, and global health developments. He makes complex medical news easy to understand.
